DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors

Information source: Galectin Therapeutics Inc.
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Colorectal Cancer; Lung Cancer; Breast Cancer; Head and Neck Cancer; Prostate Cancer

Intervention: GM-CT-01 (Drug); 5-fluorouracil (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Galectin Therapeutics Inc.

Official(s) and/or principal investigator(s):
Marilyn C Pike, M.D., Ph.D., Study Director, Affiliation: Consultant to Pro-Pharmaceuticals, Inc.

Summary

This is a Phase I, multi-center study of GM-CT-01, which has been shown to increase the anti-tumor activity of 5-fluorouracil in mice. The primary reason for doing the study is to determine the safety of GM-CT-01 given alone and in combination with therapeutical dosage of 5-Fluorouracil, in patients who have advanced cancer that can be measured by CT scan.

Clinical Details

Official title: A Phase I Open-Label Study to Evaluate the Safety and Tolerability of Escalating Doses of GM-CT-01 in the Presence and Absence of 5-Fluorouracil (5-FU) in Subjects With Advanced Solid Tumors

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Safety

Secondary outcome: Tumor progression

Detailed description: 5-Fluorouracil is a chemotherapy drug commonly used in cancer patients. Patients with different type of solid tumors who have failed standard, approved treatments can be enrolled in the study. Escalated doses of GM-CT-01 will be given alone in Cycle 1, and in combination with 5-fluorouracil in cycle 2. Patients will be on study for approximately 60 days for determination of safety. However, with patient consent treatment can continue until disease progression is determined by CT scan. The study secondary reason is to determine whether treatment has stabilize the tumors or change it in size (get bigger, smaller or stay the same)after Cycle 2 and any additional cycles of treatment.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- The subject is able to give informed consent to participate in this trial (including

all procedures and follow-up visits).

- The subject is male or female at least 18 years of age.

- The subject has a documented histologic or cytologic recurrent or metastatic solid

tumor that is not amenable to curative surgery, radiotherapy, or conventional chemotherapy of proven value.

- Subjects must have completed previous therapy (chemotherapeutic agents or other

therapies including radiation) at least 4 weeks prior to study entry.

- Following major surgery (e. g. laparotomy), > 4 weeks must have elapsed and subjects

must have recovered from effects.

- Following minor surgery (does not include insertion of vascular access device), > 2

weeks must have elapsed.

- ECOG performance status of 0-2.

- The subject has a life expectancy of at least 12 weeks.

- Female subjects must be post-menopausal, surgically sterile, or using effective

contraception. Laboratory values prior to administration of study drug:

- If female and not post-menopausal, the subject has a negative pregnancy test.

- Liver function studies: AST and ALT < 2. 5 times the upper limit of normal (ULN);

total bilirubin < 1. 5

- Hematopoietic parameters: WBC > 3000 per mm3; Granulocyte count > 1,500 per mm3;

Platelet count > 100,000 per mm3

- Renal: Creatinine < or = ULN

- Pulmonary: Dlco > or = 60% of predicted

Exclusion Criteria:

- If female, the subject is pregnant or breast feeding.

- Central nervous system (CNS) metastases or primary CNS tumors.

- The subject has a known hypersensitivity to GM-CT-01 or any of its components.

- The subject has congestive heart failure or any other medical condition that could be

adversely affected by intravenous infusion of up to approximately 200 mL of fluid over 60 minutes.

- The subject is currently abusing alcohol and/or illicit drugs.

- The subject has other significant medical, psychiatric, or social conditions which,

in the investigators' opinion, may compromise the subject's safety in participating in this study.

- In the investigators' judgment, the subject would be unreliable in adhering to the

study visit schedule or other study requirements.

- The subject is currently enrolled in a clinical trial or has participated in a

clinical trial within the 30 days prior to entry into this study.

Locations and Contacts

Florida Oncology Associates, Jacksonville, Florida 32207, United States

Ochsner Cancer Institute, New Orleans, Louisiana 70121, United States

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109, United States

Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire 03756, United States

Additional Information

Starting date: February 2003
Last updated: March 9, 2012

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017